Connect Biopharma Announces Significant Findings Regarding Rademikibart
Clinical Data on Rademikibart: Connect Biopharma announced that rademikibart significantly improved lung function and reduced acute exacerbations in patients with type 2 inflammatory asthma during a Phase 2b trial, showing better eosinophil count reductions compared to dupilumab.
Future Studies and Current Trading: The company is preparing for Phase 2 acute exacerbation studies in asthma and COPD, expected to report results in early 2026, while its stock is currently trading at $0.78 on the Nasdaq.
Trade with 70% Backtested Accuracy
Analyst Views on CNTB
About CNTB
About the author
Plus Therapeutics Prices Public Offering, Raising $15 Million
- Financing Update: Plus Therapeutics announced the pricing of 39,473,684 units at $0.38 each, expecting to raise approximately $15 million, which will provide fresh capital to advance its precision diagnostics and radiopharmaceutical programs targeting central nervous system cancers.
- Market Performance: Connect Biopharma's stock rose 5.96% to $2.31 without any new news, reflecting ongoing investor interest in its lead candidate rademikibart's new mechanism of action data and strategic priorities for 2026.
- Sector Momentum: ABVC BioPharma's shares increased by 3.37% to $2.15, suggesting that investor interest may be driven by broader momentum in the biotech sector despite the absence of new corporate updates.
- Clinical Progress: Traws Pharma's stock rose 2.82% to $1.82 following its announcement of filing a U.S. IND application for tivoxavir marboxil, further supporting investor optimism around the company's pipeline.
BTIG Affirms Buy Rating for Connect Biopharma Holdings, Keeps $10 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to exclusive stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies for market success.
Market Winning Tools: The platform provides tools and resources designed to help traders win in the markets every day.
Connect Biopharma Announces Financial Results for Q3 2025 and Offers Business Update
Clinical Trials Update: Connect Biopharma is actively recruiting participants for its Phase 2 Seabreeze STAT studies targeting acute exacerbations in asthma and COPD, with topline data expected in the first half of 2026.
Regulatory Progress: Simcere, Connect's exclusive licensee in Greater China, has submitted a New Drug Application for rademikibart for atopic dermatitis, which has been accepted by China's NMPA.
Corporate Developments: The company has terminated its American Depositary Receipt program and directly listed its ordinary shares on Nasdaq to enhance visibility and reduce costs.
Financial Overview: Connect Biopharma reported a net loss of $17.2 million for Q3 2025, with cash reserves expected to support operations into 2027, while also noting increased R&D expenses related to ongoing clinical trials.
Immuneering Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Friday
Analyst Ratings Overview: Top Wall Street analysts have recently updated their ratings on several companies, including upgrades, downgrades, and new initiations.
Korro Bio, Inc.: Clear Street analyst Bill Maughan initiated coverage with a Buy rating and a price target of $93, while the stock closed at $36.45.
THOR Industries, Inc.: Loop Capital analyst Brandon Rolle initiated coverage with a Hold rating and a price target of $110, with shares closing at $103.35.
Connect Biopharma Holdings Limited: BTIG analyst Julian Harrison initiated coverage with a Buy rating and a price target of $10, despite the stock closing at $1.55.
BTIG Begins Coverage of Connect Biopharma Holdings with a Buy Rating and Sets Price Target at $10
Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.
Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies.
Market Intelligence: Benzinga Pro is marketed as the fastest and most accurate source of stock market intelligence available.
Connect Biopharma to Participate in Two Investor Conferences This September
Upcoming Conferences: Connect Biopharma will participate in the Cantor Global Healthcare Conference on September 3, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, both featuring fireside chats.
Product Focus: The company is advancing rademikibart, an antibody targeting IL-4Rα, aimed at treating asthma and COPD, with ongoing global clinical studies addressing significant unmet needs.
Forward-Looking Statements: The press release includes forward-looking statements regarding future events, financial conditions, and product development, which are subject to various risks and uncertainties.
Regulatory Status: Rademikibart is still under clinical investigation and has not yet received approval from regulatory agencies such as the U.S. FDA or the National Medical Products Administration.
Plus Therapeutics Prices Public Offering, Raising $15 Million
- Financing Update: Plus Therapeutics announced the pricing of 39,473,684 units at $0.38 each, expecting to raise approximately $15 million, which will provide fresh capital to advance its precision diagnostics and radiopharmaceutical programs targeting central nervous system cancers.
- Market Performance: Connect Biopharma's stock rose 5.96% to $2.31 without any new news, reflecting ongoing investor interest in its lead candidate rademikibart's new mechanism of action data and strategic priorities for 2026.
- Sector Momentum: ABVC BioPharma's shares increased by 3.37% to $2.15, suggesting that investor interest may be driven by broader momentum in the biotech sector despite the absence of new corporate updates.
- Clinical Progress: Traws Pharma's stock rose 2.82% to $1.82 following its announcement of filing a U.S. IND application for tivoxavir marboxil, further supporting investor optimism around the company's pipeline.
BTIG Affirms Buy Rating for Connect Biopharma Holdings, Keeps $10 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to exclusive stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies for market success.
Market Winning Tools: The platform provides tools and resources designed to help traders win in the markets every day.
Connect Biopharma Announces Financial Results for Q3 2025 and Offers Business Update
Clinical Trials Update: Connect Biopharma is actively recruiting participants for its Phase 2 Seabreeze STAT studies targeting acute exacerbations in asthma and COPD, with topline data expected in the first half of 2026.
Regulatory Progress: Simcere, Connect's exclusive licensee in Greater China, has submitted a New Drug Application for rademikibart for atopic dermatitis, which has been accepted by China's NMPA.
Corporate Developments: The company has terminated its American Depositary Receipt program and directly listed its ordinary shares on Nasdaq to enhance visibility and reduce costs.
Financial Overview: Connect Biopharma reported a net loss of $17.2 million for Q3 2025, with cash reserves expected to support operations into 2027, while also noting increased R&D expenses related to ongoing clinical trials.
Immuneering Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Friday
Analyst Ratings Overview: Top Wall Street analysts have recently updated their ratings on several companies, including upgrades, downgrades, and new initiations.
Korro Bio, Inc.: Clear Street analyst Bill Maughan initiated coverage with a Buy rating and a price target of $93, while the stock closed at $36.45.
THOR Industries, Inc.: Loop Capital analyst Brandon Rolle initiated coverage with a Hold rating and a price target of $110, with shares closing at $103.35.
Connect Biopharma Holdings Limited: BTIG analyst Julian Harrison initiated coverage with a Buy rating and a price target of $10, despite the stock closing at $1.55.
BTIG Begins Coverage of Connect Biopharma Holdings with a Buy Rating and Sets Price Target at $10
Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.
Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies.
Market Intelligence: Benzinga Pro is marketed as the fastest and most accurate source of stock market intelligence available.
Connect Biopharma to Participate in Two Investor Conferences This September
Upcoming Conferences: Connect Biopharma will participate in the Cantor Global Healthcare Conference on September 3, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, both featuring fireside chats.
Product Focus: The company is advancing rademikibart, an antibody targeting IL-4Rα, aimed at treating asthma and COPD, with ongoing global clinical studies addressing significant unmet needs.
Forward-Looking Statements: The press release includes forward-looking statements regarding future events, financial conditions, and product development, which are subject to various risks and uncertainties.
Regulatory Status: Rademikibart is still under clinical investigation and has not yet received approval from regulatory agencies such as the U.S. FDA or the National Medical Products Administration.
